

Special Issue

Cell and Gene Therapy of Cancer

Message from the Guest Editors

Gene therapeutics have been evolving at a rapid pace since the 1990s, and as of 2020, there are 16 types of gene therapeutics that have been commercialized throughout the world. Among these gene therapeutic candidates, virus-mediated gene therapeutics have been approved in Europe (2012) and two other gene therapeutics have been approved in the USA and Europe (2015 and 2016). Based on this current trend, the gene and cell therapeutics field is expected to expand and transform more rapidly. We will highlight the most cutting-edge discoveries in the translational development of bio-molecular therapeutics for cancer via this issue. Furthermore, as always, our unique focus on development gene and cell therapeutics will allow us to highlight the most exciting high-impact findings. We will discuss recent advancements and developments in the following areas: (1) oncolytic viruses—specific targeting of tumor and tumor microenvironment, and the tumor-specific expression of therapeutic genes, (2) genetically armed immune regulatory cells/adaptive immune therapies, (3) cancer vaccination strategies, (4) targeting of neo-antigens and tumor stem cells, and (5) non-viral vector delivery.

Guest Editors

Prof. Dr. Chae-OK Yun

Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea

Prof. A-Rum Yoon

Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea

Deadline for manuscript submissions

closed (31 January 2021)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/57153

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).